Symptoms of the viral disease include intense weakness, muscle pain, headaches and a sore throat, vomiting, diarrhoea and rashes, among others.Īlthough it has no vaccine, WHO has previously said the Sudan strain is less transmissible and has shown a lower fatality rate in previous outbreaks than Ebola Zaire. Tedros did not provide details of the vaccines due for trial such as their names or which firms developed them.Įbola, a hemorrhagic fever, mainly spreads through contact with the bodily fluids of an infected person. "Our primary focus now is to rapidly control and contain this outbreak to protect neighbouring districts as well as neighbouring countries." Two of those vaccines "could be put in clinical trial in Uganda in the coming weeks pending regulatory and other approvals from the Ugandan government," he said. Designed for investigators, research coordinators, CRO personnel, students, and others who have a desire to learn about clinical trials, this manual begins with an overview of the historical framework of clinical research, and leads the reader through a discussion of safety concerns and resulting regulations. After the program reverts to an EndNote Viewer, you will still. After those 30 days are up, the program will revert to a feature-restricted EndNote Viewer. You will have 30 days after you first use the program to evaluate EndNote and all of its features. In a virtual address to a meeting of Africa regional health officials in Kampala, Tedros said several vaccines were currently being developed that could deal with the Sudan strain. The EndNote desktop trial will work as a fully functional program during the trial period. The epicentre of the infections is a cluster of five districts in central Uganda. There have been worries the spread of infection in Uganda could be difficult to control because currently there is no vaccine for the Sudan strain.
0 kommentar(er)
